- Recommendation ID
- NG191/7
- Question
What is the effectiveness, cost effectiveness and safety of using a combination of casirivimab and imdevimab at doses other than 8 g for treating COVID-19?
- Any explanatory notes
(if applicable) Suggested PICO (Population, Intervention, Comparator, Outcome)
P: people hospitalised because of COVID-19
I: treatment with different doses of casirivimab and imdevimab
C:
• recommended dose against different doses
• standard care against recommended dose and/or different doses
O:
• mortality
• progression to invasive mechanical ventilation
• progression to non-invasive respiratory support
• duration of hospitalisation
• adverse events
• costs of treatment
• health-related quality of life
Source guidance details
- Comes from guidance
- COVID-19 rapid guideline: managing COVID-19
- Number
- NG191
- Date issued
- March 2021
Other details
| Is this a recommendation for the use of a technology only in the context of research? | No |
| Is it a recommendation that suggests collection of data or the establishment of a register? | No |
| Last Reviewed | 12/11/2021 |